

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

FURTHER UPDATE ON THE USE OF PROCEEDS FROM THE ISSUE OF SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”, together with the subsidiaries, the “**Group**”) dated 9 February 2018, 12 February 2018, 14 March 2018 and 18 June 2021 (collectively, the “**Announcements**”) in relation to issue of 199,500,000 new H shares of the Company to the subscribers under the general mandate pursuant to the subscription agreements entered into between the Company and each of the subscribers, respectively. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcements.

The net proceeds from the Subscription, after deducting the relevant expenses incurred in relation to the Subscription, amounted to approximately HK\$49,225,000 (the “**Net Proceeds**”). As disclosed in the Announcements, the Net Proceeds were intended to be used for the further development of the Company’s overall planning of the business fields, including but not limited to the provision of elderly care service and the operation and management business integrating medical and care services. (the “**Intended Use**”).

The Company wishes to update the Shareholders and potential investors that, since completion of the Subscription and as at the date of this announcement, approximately HK\$45.43 million of the Net Proceeds (equivalent to approximately RMB39.28 million) were utilised by the Group in accordance with the Intended Use, details of which are as follows:

- (i) approximately HK\$34.71 million (equivalent to approximately RMB30.01 million), representing approximately 70.51% of the Net Proceeds, were utilised for the expansion of the Group’s elderly care and healthcare business; and

(ii) approximately HK\$10.72 million (equivalent to approximately RMB9.27 million), representing approximately 21.78% of the Net Proceeds, were utilised for improving the electroencephalography (EEG) detection services the Group provides.

Based on the above, as at the date of this announcement, the amount of unutilised Net Proceeds is approximately HK\$3.79 million (equivalent to approximately RMB3.28 million). Such amount will be utilised by the Group in accordance with the Intended Use as and when appropriate after taking into account the actual needs of the Group and the general business environment.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC, 21 June 2021

For the purpose of this announcement, translations of Renminbi into Hong Kong dollars or vice versa have been calculated by using an exchange rate of RMB1.00 equal to HK\$0.8645. Such exchange rate has been used, where applicable, for the purpose of illustration only and does not constitute a representation that any amounts were, may have been or will be exchanged at such rate or any other rates or at all.

As at the date of this announcement, the executive Directors are Sun Li, Hao Zhihui and He Xin; the non-executive Directors are Cao Aixin and Li Ximing; the independent non-executive Directors are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page on the GEM website at www.hkgem.com for at least seven days from the date of its posting. This announcement will also be published and remain on the website of the Company at www.bioteda.com.